Retatrutide, developed by Soma, represents a promising breakthrough in metabolic regulation. This dual-action medication combines incretin receptor properties with GIP pathway activation , showing remarkable potential in clinical data for metabolic loss . Scientists believe this treatment could offer a alternative pathway for people facing excess w